Heather N. Allen
Research Interests
Heather N. Allen has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Andrew J. Todd
School of Psychology and Neuroscience, Sir James Black Building, University of Glasgow, Glasgow, G12 8QQ, UK
1 shared publication - Bradley K. Taylor
Department of Anesthesiology and Perioperative Medicine, Department of Pharmacology, Pittsburgh Center for Pain Research, and Pittsburgh Project to End Opioid Misuse, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
1 shared publication - Cynthia M. Arokiaraj
Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, USA
1 shared publication - Diogo Francisco Silva Santos
University of Pittsburgh, Pittsburgh, PA USA
1 shared publication Eileen Nguyen
Center for Neuroscience
1 shared publication- Paramita Basu
Department of Anesthesiology and Perioperative Medicine, Department of Pharmacology, Pittsburgh Center for Pain Research, and Pittsburgh Project to End Opioid Misuse, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
1 shared publication
Latest Publications
- Open Access
- 22 November 2023
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (22)
Alleviation of neuropathic pain with neuropeptide Y requires spinal Npy1r interneurons that coexpress Grp
Neuropeptide Y targets the Y1 receptor (Y1) in the spinal dorsal horn (DH) to produce endogenous and exogenous analgesia. DH interneurons that express Y1 (Y1-INs; encoded by Npy1r ) are necessary and sufficient for neuropathic hypersensitivity after peripheral nerve injury. However, as Y1-INs are heterogenous in composition in terms of morphology, neurophysiological characteristics, and gene expression, we hypothesized that a more precisely defined subpopulation mediates neuropathic hypersensitivity. Using fluorescence in situ hybridization, we found that Y1-INs segregate into 3 largely nonoverlapping subpopulations defined by the coexpression of Npy1r with gastrin-releasing peptide ( Grp / Npy1r ), neuropeptide FF ( Npff / Npy1r ), and cholecystokinin ( Cck / Npy1r ) in the superficial DH of mice, nonhuman primates, and humans. Next, we analyzed the functional significance of Grp / Npy1r , Npff / Npy1r , and Cck / Npy1r INs to neuropathic pain using a mouse model of peripheral nerve injury. We found that chemogenetic inhibition of Npff / Npy1r -INs did not change the behavioral signs of neuropathic pain. Further, inhibition of Y1-INs with an intrathecal Y1 agonist, [Leu 31 , Pro 34 ]-NPY, reduced neuropathic hypersensitivity in mice with conditional deletion of Npy1r from CCK-INs and NPFF-INs but not from GRP-INs. We conclude that Grp / Npy1r -INs are conserved in higher order mammalian species and represent a promising and precise pharmacotherapeutic target for the treatment of neuropathic pain.
- 22 November 2023
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (22)
Open AccessAlleviation of neuropathic pain with neuropeptide Y requires spinal Npy1r interneurons that coexpress Grp
Neuropeptide Y targets the Y1 receptor (Y1) in the spinal dorsal horn (DH) to produce endogenous and exogenous analgesia. DH interneurons that express Y1 (Y1-INs; encoded by Npy1r ) are necessary and sufficient for neuropathic hypersensitivity after peripheral nerve injury. However, as Y1-INs are heterogenous in composition in terms of morphology, neurophysiological characteristics, and gene expression, we hypothesized that a more precisely defined subpopulation mediates neuropathic hypersensitivity. Using fluorescence in situ hybridization, we found that Y1-INs segregate into 3 largely nonoverlapping subpopulations defined by the coexpression of Npy1r with gastrin-releasing peptide ( Grp / Npy1r ), neuropeptide FF ( Npff / Npy1r ), and cholecystokinin ( Cck / Npy1r ) in the superficial DH of mice, nonhuman primates, and humans. Next, we analyzed the functional significance of Grp / Npy1r , Npff / Npy1r , and Cck / Npy1r INs to neuropathic pain using a mouse model of peripheral nerve injury. We found that chemogenetic inhibition of Npff / Npy1r -INs did not change the behavioral signs of neuropathic pain. Further, inhibition of Y1-INs with an intrathecal Y1 agonist, [Leu 31 , Pro 34 ]-NPY, reduced neuropathic hypersensitivity in mice with conditional deletion of Npy1r from CCK-INs and NPFF-INs but not from GRP-INs. We conclude that Grp / Npy1r -INs are conserved in higher order mammalian species and represent a promising and precise pharmacotherapeutic target for the treatment of neuropathic pain.